Top

Published in:

01-04-2011 | Letter

Optimizing locoregional staging in the preoperative setting of resectable esophageal cancer

Authors: Charalambos Batsis, Ioannis Makris

Published in: Surgical Endoscopy | Issue 4/2011

Excerpt

As preoperative, also called neoadjuvant, chemoradiotherapy has increasingly been incorporated into clinical practice for the multimodal treatment of resectable esophageal cancer, there is an increased interest in how accurately the clinical stage (cTNM) needs to be predicted before the initiation of neoadjuvant treatment, staging (yTNM), subsequent surgery, and final histopathologic examination of the surgical specimen (pTNM staging). …

Erasmus JJ, Munden RF (2007) The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol 17:29–37PubMedCrossRef

Choi J, Kim SG, Kim JS, Jung HC, Song IS (2010) Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 24:1380–1386PubMedCrossRef

Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17PubMedCrossRef

Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16:795–798PubMedCrossRef

Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360:1362 (author reply 1363)PubMedCrossRef

Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681PubMedCrossRef

Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247:714–715PubMedCrossRef

Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48PubMedCrossRef

Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995PubMedCrossRef

10.

Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9:1413–1416PubMedCrossRef

11.

Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9:389–392PubMedCrossRef

12.

Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16:774–775PubMedCrossRef

13.

Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287PubMedCrossRef

14.

Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRef

15.

Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRef

16.

Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782

17.

Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068PubMedCrossRef

18.

Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRef

19.

Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28(17):e279–e280; author reply e282–3PubMedCrossRef

20.

Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7(4):347–350CrossRef

Title: Optimizing locoregional staging in the preoperative setting of resectable esophageal cancer
Authors: Charalambos Batsis
Ioannis Makris
Publication date: 01-04-2011
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 4/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-010-1283-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Optimizing locoregional staging in the preoperative setting of resectable esophageal cancer

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2011

Defining the learning curve in laparoscopic paraesophageal hernia repair: a CUSUM analysis

Validation of a novel laparoscopic adjustable gastric band simulator

Laparoscopic versus open appendectomy for acute appendicitis: a metaanalysis

Initial experiences using robot-assisted central pancreatectomy with pancreaticogastrostomy: a potential way to advanced laparoscopic pancreatectomy

Optimizing locoregional staging in the preoperative setting of resectable esophageal cancer

Who should decide the best minimally invasive approach? Should we listen to our patients?